UNSPSC 51123107: Dofetilide

This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C19H27N3O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) R4Z9X1N2ND, chemically known as uk 68,798 but more generally known as dofetilide, which bears US NIH Compound Identifier 71329. European Medicines Agency schedules Dofetilide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06351MIG.

UNSPSC 51123107 Dofetilide, a Commodity code, represents injectable and oral pharmaceuticals for emergency and chronic cardiac care purchased by state health agencies, municipal fire rescue departments, and cooperative purchasing alliances serving multiple state and local jurisdictions. State and local buyers under this code procure specific medication line items—including dofetilide and related antiarrhythmic, vasopressor, and hemodynamic support drugs—for deployment in advanced life support protocols, hospital formularies, and state pharmacy benefit programs. The issuing bodies span municipal fire-rescue services, state health and human services commissions managing Medicaid and employee health plans, and multistate cooperative purchasing organizations coordinating procurement across dozens of member jurisdictions. Recent solicitations show buyers emphasizing firm pricing, expedited delivery (often within ten calendar days), minimum shelf-life requirements (typically six to nine months remaining at receipt), and compliance with cGMP, DSCSA, FDA requirements, and OSHA hazard communication standards.

Activity under the code clusters in Florida, Texas, and Minnesota, with the multistate cooperative vehicle (MMCAP) extending reach to Oregon and other participating states. Representative recent opportunities include the City of Tampa Fire Rescue's sealed-bid procurement (IFB 26P00188, due April 8, 2026) for advanced life support medications including epinephrine, adenosine, labetalol, and diltiazem—an estimated $40,000 annual contract with a 5 percent SLBE bid discount available—and the Minnesota Multistate Cooperative Purchasing Alliance's RFP (S1070000015802, due March 26, 2026) to establish multi-award generic pharmaceutical contracts through three authorized wholesalers effective July 1, 2026, with price competitiveness weighted at 75 percent. The Texas HHS Commission issued an RFI (HHS0017013, April 3, 2026 deadline) exploring direct-to-manufacturer prescription delivery models to inform future pharmacy benefit procurement strategy, signaling potential expansion of state-level medication sourcing outside traditional PBM and GPO channels.